Summary of findings for the main comparison. Mortality with anti‐gram‐positive antibiotics compared to placebo for the treatment of febrile neutropenic patients with cancer.

Mortality with anti‐gram‐positive antibiotics compared to placebo for the treatment of febrile neutropenic patients with cancer
Patient or population: febrile neutropenic patients with cancer Setting: in‐hospital Intervention: anti‐gram‐positive antibiotics Comparison: placebo or added anti‐gram‐positive antibiotics
Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	№ of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with placebo	Risk with anti gram‐positive antibiotics
Overall mortality	Study population		RR 0.90 (0.64 to 1.25)	1242 (8 RCTs)	⊕⊕⊕⊝ MODERATE 1 2
	104 per 1,000	94 per 1,000 (67 to 130)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence High quality: We are very confident that the true effect lies close to that of the estimate of the effect Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

¹ Lack of blinding should not affect the objective outcome of mortality

² Wide CI ranging from a large benefit of anti‐gram‐positive antibiotics to possible harm